Impact of pregnancy/childbirth on dispositional optimism in the context of risk of depression, mental health status and satisfaction with life
Conclusions: Pregnant women from Belarus had a higher level of optimism than other countries. Non-pregnant women had an average level of optimism. Future studies should include larger groups of women and consider other factors that may additionally contribute to dispositional optimism (Source: Frontiers in Psychiatry)
Source: Frontiers in Psychiatry - January 8, 2024 Category: Psychiatry Source Type: research

The Development of the Combination Drug Leukovir ® Tablets for the Treatment of Multiple Sclerosis: A Comprehensive Review
Curr Drug Targets. 2023 Nov 30. doi: 10.2174/0113894501272301231124074141. Online ahead of print.ABSTRACTThe review is devoted to the development and study of the drug Leukovir® (cladribine+ ribavirin) and its use in the treatment of relapsing-remitting and secondary progressive forms of multiple sclerosis, a chronic neurodegenerative disease aiming the risk reduction of relapse and progression of a disability. In clinical trials Leukovir® has proved to be efficient by up to 56 weeks for the treatment of relapsing-remitting and secondary progressive forms of multiple sclerosis. The drug is registered in the Republic of B...
Source: Current Drug Targets - December 1, 2023 Category: Drugs & Pharmacology Authors: Elena Kalinichenko Svetlana Babitskaya Source Type: research

The Development of the Combination Drug Leukovir ® Tablets for the Treatment of Multiple Sclerosis: A Comprehensive Review
Curr Drug Targets. 2023 Nov 30. doi: 10.2174/0113894501272301231124074141. Online ahead of print.ABSTRACTThe review is devoted to the development and study of the drug Leukovir® (cladribine+ ribavirin) and its use in the treatment of relapsing-remitting and secondary progressive forms of multiple sclerosis, a chronic neurodegenerative disease aiming the risk reduction of relapse and progression of a disability. In clinical trials Leukovir® has proved to be efficient by up to 56 weeks for the treatment of relapsing-remitting and secondary progressive forms of multiple sclerosis. The drug is registered in the Republic of B...
Source: Current Drug Targets - December 1, 2023 Category: Drugs & Pharmacology Authors: Elena Kalinichenko Svetlana Babitskaya Source Type: research

The Development of the Combination Drug Leukovir ® Tablets for the Treatment of Multiple Sclerosis: A Comprehensive Review
Curr Drug Targets. 2023 Nov 30. doi: 10.2174/0113894501272301231124074141. Online ahead of print.ABSTRACTThe review is devoted to the development and study of the drug Leukovir® (cladribine+ ribavirin) and its use in the treatment of relapsing-remitting and secondary progressive forms of multiple sclerosis, a chronic neurodegenerative disease aiming the risk reduction of relapse and progression of a disability. In clinical trials Leukovir® has proved to be efficient by up to 56 weeks for the treatment of relapsing-remitting and secondary progressive forms of multiple sclerosis. The drug is registered in the Republic of B...
Source: Current Drug Targets - December 1, 2023 Category: Drugs & Pharmacology Authors: Elena Kalinichenko Svetlana Babitskaya Source Type: research

The Development of the Combination Drug Leukovir ® Tablets for the Treatment of Multiple Sclerosis: A Comprehensive Review
Curr Drug Targets. 2023 Nov 30. doi: 10.2174/0113894501272301231124074141. Online ahead of print.ABSTRACTThe review is devoted to the development and study of the drug Leukovir® (cladribine+ ribavirin) and its use in the treatment of relapsing-remitting and secondary progressive forms of multiple sclerosis, a chronic neurodegenerative disease aiming the risk reduction of relapse and progression of a disability. In clinical trials Leukovir® has proved to be efficient by up to 56 weeks for the treatment of relapsing-remitting and secondary progressive forms of multiple sclerosis. The drug is registered in the Republic of B...
Source: Current Drug Targets - December 1, 2023 Category: Drugs & Pharmacology Authors: Elena Kalinichenko Svetlana Babitskaya Source Type: research

The Development of the Combination Drug Leukovir ® Tablets for the Treatment of Multiple Sclerosis: A Comprehensive Review
Curr Drug Targets. 2023 Nov 30. doi: 10.2174/0113894501272301231124074141. Online ahead of print.ABSTRACTThe review is devoted to the development and study of the drug Leukovir® (cladribine+ ribavirin) and its use in the treatment of relapsing-remitting and secondary progressive forms of multiple sclerosis, a chronic neurodegenerative disease aiming the risk reduction of relapse and progression of a disability. In clinical trials Leukovir® has proved to be efficient by up to 56 weeks for the treatment of relapsing-remitting and secondary progressive forms of multiple sclerosis. The drug is registered in the Republic of B...
Source: Current Drug Targets - December 1, 2023 Category: Drugs & Pharmacology Authors: Elena Kalinichenko Svetlana Babitskaya Source Type: research

Viruses, Vol. 15, Pages 2325: Nine Years of African Swine Fever in Poland
Conclusions: During the nine years of ASF in Poland, multiple measures have been taken to prevent the spread of the virus among the wild boar population via the passive and active surveillance of these animals. With regard to pig farms, the only effective measure for preventing the spread of ASF is the efficient enforcement by state authorities of the biosecurity standards and the farmers’ compliance with them. (Source: Viruses)
Source: Viruses - November 27, 2023 Category: Virology Authors: Mateusz Kruszy ński Kacper Śróda Ma łgorzata Juszkiewicz Dominika Siuda Monika Olszewska Grzegorz Wo źniakowski Tags: Review Source Type: research

Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial
Lancet Respir Med. 2023 Nov 15:S2213-2600(23)00389-2. doi: 10.1016/S2213-2600(23)00389-2. Online ahead of print.ABSTRACTBACKGROUND: Around 500 000 people worldwide develop rifampicin-resistant tuberculosis each year. The proportion of successful treatment outcomes remains low and new treatments are needed. Following an interim analysis, we report the final safety and efficacy outcomes of the TB-PRACTECAL trial, evaluating the safety and efficacy of oral regimens for the treatment of rifampicin-resistant tuberculosis.METHODS: This open-label, randomised, controlled, multi-arm, multicentre, non-inferiority trial was conducte...
Source: Respiratory Care - November 19, 2023 Category: Respiratory Medicine Authors: Bern-Thomas Nyang'wa Catherine Berry Emil Kazounis Ilaria Motta Nargiza Parpieva Zinaida Tigay Ronelle Moodliar Matthew Dodd Varvara Solodovnikova Irina Liverko Shakira Rajaram Mohammed Rassool Timothy McHugh Melvin Spigelman David A Moore Koert Ritmeijer Source Type: research

Threats to conservation from national security interests
This article is protected by copyright. All rights reserved.PMID:37768190 | DOI:10.1111/cobi.14193 (Source: Conservation Biology)
Source: Conservation Biology - September 28, 2023 Category: Biology Authors: Katarzyna Nowak Dinah Bear Anwesha Dutta Myles Traphagen Micha ł Żmihorski Bogdan Jaroszewicz Source Type: research

Threats to conservation from national security interests
This article is protected by copyright. All rights reserved.PMID:37768190 | DOI:10.1111/cobi.14193 (Source: Conservation Biology)
Source: Conservation Biology - September 28, 2023 Category: Biology Authors: Katarzyna Nowak Dinah Bear Anwesha Dutta Myles Traphagen Micha ł Żmihorski Bogdan Jaroszewicz Source Type: research

Threats to conservation from national security interests
This article is protected by copyright. All rights reserved.PMID:37768190 | DOI:10.1111/cobi.14193 (Source: Conservation Biology)
Source: Conservation Biology - September 28, 2023 Category: Biology Authors: Katarzyna Nowak Dinah Bear Anwesha Dutta Myles Traphagen Micha ł Żmihorski Bogdan Jaroszewicz Source Type: research

Threats to conservation from national security interests
This article is protected by copyright. All rights reserved.PMID:37768190 | DOI:10.1111/cobi.14193 (Source: Conservation Biology)
Source: Conservation Biology - September 28, 2023 Category: Biology Authors: Katarzyna Nowak Dinah Bear Anwesha Dutta Myles Traphagen Micha ł Żmihorski Bogdan Jaroszewicz Source Type: research

Threats to conservation from national security interests
This article is protected by copyright. All rights reserved.PMID:37768190 | DOI:10.1111/cobi.14193 (Source: Conservation Biology)
Source: Conservation Biology - September 28, 2023 Category: Biology Authors: Katarzyna Nowak Dinah Bear Anwesha Dutta Myles Traphagen Micha ł Żmihorski Bogdan Jaroszewicz Source Type: research

Threats to conservation from national security interests
This article is protected by copyright. All rights reserved.PMID:37768190 | DOI:10.1111/cobi.14193 (Source: Conservation Biology)
Source: Conservation Biology - September 28, 2023 Category: Biology Authors: Katarzyna Nowak Dinah Bear Anwesha Dutta Myles Traphagen Micha ł Żmihorski Bogdan Jaroszewicz Source Type: research

Threats to conservation from national security interests
This article is protected by copyright. All rights reserved.PMID:37768190 | DOI:10.1111/cobi.14193 (Source: Conservation Biology)
Source: Conservation Biology - September 28, 2023 Category: Biology Authors: Katarzyna Nowak Dinah Bear Anwesha Dutta Myles Traphagen Micha ł Żmihorski Bogdan Jaroszewicz Source Type: research